Journal
New England Journal of Medicine
Publication Date
2019
Volume
381
Issue
5
First Page
432
Last Page
443
Document Type
Open Access Publication
DOI
10.1056/NEJMoa1817073
Rights and Permissions
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S., Barrientos, J., . . . Tallman, M. (2019). Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 381(5), 432-443. doi:10.1056/NEJMoa1817073 Copyright © 2019 Massachusetts Medical Society https://www.nejm.org/doi/full/10.1056/NEJMoa1817073
Recommended Citation
Cashen, Amanda F. and al., et, "Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia." New England Journal of Medicine. 381, 5. 432 - 443. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8027
